BioPharm America™ 2016: Has the IPO window closed?

September 29, 2016
After outperforming the rest of the field for three straight years, the end of Q2 showed a decided chill in the market toward recent biotech IPOs. Has the window of opportunity closed? If so, what are the ramifications for those who had long anticipated debuts but are currently trading below issue price? Will we see increased partnerships with pharma to fund programs and operations? See a candid discussion on what this will mean for companies looking to fund in the future, for those still in line to IPO by year end and for those now facing the ramifications of falling share prices.
Previous Video
BioPharm America™ 2016: What makes a serial entrepreneur so successful and what makes them tick?
BioPharm America™ 2016: What makes a serial entrepreneur so successful and what makes them tick?

Who are the top serial entrepreneurs in biotech? What kind of person does it take to enter a company at the...

Next Video
BPA16 The Intersection of technology and medicine
BPA16 The Intersection of technology and medicine